Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Reversible host cell surface remodelling limits immune recognition and maximizes survival of Plasmodium falciparum gametocytes
Ngotho P. et al, (2025), PLOS PATHOGENS, 21
Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults.
Kinyua AW. et al, (2024), The Journal of infection, 89
Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
Rosenkranz M. et al, (2024), Life science alliance, 7
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama IN. et al, (2024), Immunity, 57, 1215 - 1224.e6
Social, Ethical and Regulatory implications of conducting a malaria Vaccine Efficacy trial in a human infection study in Kenya (SERVE-Kenya): A study protocol
Chi PC. et al, (2024), Wellcome Open Research, 9, 193 - 193
Fourth Controlled Human Infection Model (CHIM) meeting – CHIMs in endemic countries, May 22–23, 2023
Kapulu M. et al, (2024), Biologicals, 85, 101747 - 101747
Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.
Kapulu MC. et al, (2024), Frontiers in immunology, 15
Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.
Kibwana E. et al, (2024), 445, 337 - 365
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023
Cavaleri M. et al, (2024), Biologicals
The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study.
Kariuki SN. et al, (2023), eLife, 12
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Science translational medicine, 15
Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.
Barnes MVC. et al, (2023), Immunotherapy advances, 3
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang S. et al, (2023), Wellcome open research, 8
Sporozoite immunization: innovative translational science to support the fight against malaria.
Richie TL. et al, (2023), Expert review of vaccines, 22, 964 - 1007
Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response
Kapulu MC. et al, (2022), BMC Infectious Diseases, 22